Information Provided By: 
Fly News Breaks for May 19, 2015
BLUE
May 19, 2015 | 08:57 EDT
Piper Jaffray sees upside potential to its expectation that LentiGlobin will launch in 2020 after the bluebird bio this morning provided a regulatory update. Piper believes approval in Europe for treatment of beta-thal major could come as much as three years earlier than expected while approval in the U.S. is likely to be ahead of expectations as well. The firm reiterates an Overweight rating on bluebird with a $186 price target.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
